An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AlloVir to Participate in the SVB Securities Global Biopharma Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
AlloVir, Inc. (NASDAQ: ALVR) announced that CEO Diana Brainard, M.D., will engage in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:00 a.m. ET. The event will be available via live webcast and archived replay on the Investors & Press section of AlloVir's website. AlloVir specializes in T-cell immunotherapy, focusing on treating patients with weakened immune systems. The company's innovative technology allows for the treatment of various viral diseases using allogeneic T cells. For updates, visit AlloVir's website.
Positive
None.
Negative
None.
WALTHAM, Mass.--(BUSINESS WIRE)--
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced that Chief Executive Officer Diana Brainard, M.D., will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 10:00 a.m. ET.
A live webcast and archived replay of the fireside chat will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com.
About AlloVir
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter or LinkedIn.
